<DOC>
	<DOCNO>NCT00095160</DOCNO>
	<brief_summary>Study 1493-852A phase 1 study primary objective determine safety high tolerate dose experimental immune response modifier administer intravenously patient solid organ tumor responsive currently available treatment . The secondary objective study monitor tumor response form treatment .</brief_summary>
	<brief_title>Safety Study Immune Response Modifier Patients With Refractory Solid Organ Tumors</brief_title>
	<detailed_description />
	<criteria>Have solid organ tumor refractory currently available treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Have life expectancy 4 month Have normal organ bone marrow function Have biologic , hormonal , antineoplastic chemotherapy , radiation therapy within 4 week prior 1st dose study drug recover adverse event agent administer 4 week earlier . Use investigational agent 4 week prior 1st dose study drug Use immunosuppressive therapy 4 week prior 1st dose Have history , clinical evidence , myocardial ischemia , congestive heart failure , myocardial arrhythmia require treatment within past 6 month Have uncontrolled intercurrent chronic illness , limited , ongoing active infection hepatitis B C , immune dysfunction autoimmune disease , endocrine dysfunction hypo hyperthyroidism , psychiatric illness depression suicidal tendency social situation would limit compliance study requirement Have history disease require ongoing steroid treatment Have history seizure disorder uncontrolled medication Have history clinically significant coagulation bleed disorder abnormality Are HIV positive . HIV positive subject exclude study possible interaction immunomodulatory effect 852A potential pharmacokinetic interaction associate combination retroviral therapy . Are pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Solid Organ Tumors</keyword>
</DOC>